Abstract:Substantial elevation in thrombospondin 1 (TSP1)‐plasma levels have been consistently implicated in in pathogenesis of a variety of fatal cardiovascular conditions, such as ischemia‐reperfusion injury, pulmonary hypertension and coronary artery disease. While domain mapping on monomeric TSP1 reveals a broad interaction network, up to 83 ligands and receptors, TSP1‐initiated signal cascades through its cognate receptor CD47 (a ubiquitous plasma membrane protein) have been directly correlated with cardiovascular dysfunction. There is only one systemic monoclonal antibody ‐ currently in clinical phase I ‐ to interfere with TSP1 and its network, and it is indicated for cancer therapy. Our work provides “proof‐of‐concept” of a novel anti‐TSP1 pharmacological strategy, relying on extraneous administration of recombinant human CD47‐derived peptide (rh‐CD47p), which serves two distinct, yet equally important goals: First, exogenous rh‐CD47p functions as a circulating decoy receptor protein to specifically bind TSP1 molecules, which are abnormally elevated in plasma. Consequently, rh‐CD47p‐bound TSP1 cannot bind its endogenous receptor CD47 expressed on vascular endothelium, leading to mitigation of all intracellular down‐stream molecules, and improvement of TSP1‐inhibited vasodilation. The second aim can be better achieved via adopting a pharmaceutical liposomal system. Multiple rh‐CD47p coupled onto each nano‐liposome can bind several circulating TSP1 molecles, leading to formation of many complexes between liposomal‐rh‐CD47p and TSP1, which can then be rapidly eliminated via the reticulo‐endothelial system. In principle, the recombinant decoy protein rh‐CD47p is “nano‐modified” into a therapeutic platform to eliminate pathological excess of TSP1 from circulation. Our pilot studies were carried out in an ex vivo model using isolated mouse thoracic aortic segments. Initially, a pre‐treatment protocol for rh‐CD47p (added 15 min prior to TSP1 incubation) was shown to significantly ameliorate the TSP1‐impairement of endothelium‐dependent vasodilation ( p <0.0001, rh‐CD47p+TSP1 vs. TSP1; p >0.05 rh‐CD47p+TSP1 vs. control, n=6). To mimic pre‐existing high circulating levels of TSP1 in patients, a reverse order of incubation was investigated. In this post‐treatment set‐up, where TSP1 incubation was started 15 min prior to rh‐CD47p addition, a marked reversal of TSP1‐impaired vasodilation was observed, back to the same level as controls ( p <0.0001 rh‐CD47p+TSP1 vs. TSP1; p >0.05 rh‐CD47p+TSP1 vs. control, n=4). Simultaneously, titration of the binding molar ratios of rh‐CD47p:TSP1 was examined, in order to find the optimal dose of rh‐CD47p for maximum recovery from TSP1‐induced vascular impairment. Stoichiometric binding of rh‐CD47p and TSP1, at different incremental ratios, was further confirmed via western blotting, and immune‐precipitation, both in cell‐free setting. Our current results indicate the feasibility of exogenous administration of rh‐CD47p as a unique pharmacological strategy to improve TSP1‐impaired endothelium‐dependent vasodilation, thus providing a solid foundation for our novel decoy CD47‐coated nano‐formulation for TSP1‐associated cardiovascular complications. Support or Funding Information Midwestern University intramural funding

Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke

In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody

TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation

Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor

Influence of Thrombolysis on the Safety and Efficacy of Blocking Platelet Adhesion or Secretory Activity in Acute Ischemic Stroke in Mice

Termination of bleeding by a specific, anticatalytic antibody against plasmin

A Novel HLA-DRα1-MOG-35-55 Construct Treats Experimental Stroke

Erythrocyte-Inspired Discoidal Polymeric Nanoconstructs Carrying Tissue Plasminogen Activator for the Enhanced Lysis of Blood Clots

Amino-Fucoidan as a Vector for rtPA-Induced Fibrinolysis in Experimental Thrombotic Events

Targeting Thymidine Phosphorylase With Tipiracil Hydrochloride Attenuates Thrombosis Without Increasing Risk of Bleeding in Mice

Abstract 398: Inhibition of Tissue Factor Reduces Thrombosis and Inflammation Without Increased Bleeding in a Mouse Model of Ischemic Stroke

Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs

A Novel Hirudin Derivative Inhibiting Thrombin Without Bleeding for Subcutaneous Injection.

Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus

Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Mice Are Susceptible to Intracerebral Thrombosis and Ischemic Stroke

Single- and two- chain tissue type plasminogen activator treatments differentially influence cerebral recovery after stroke

Evaluation of thrombomodulin/thrombin activatable fibrinolysis inhibitor function in plasma using tissue-type plasminogen activator-induced plasma clot lysis time

Parabiosis Discriminates the Circulating, Endothelial, and Parenchymal Contributions of Endogenous Tissue-Type Plasminogen Activator to Stroke

Novel Pharmaceutical Strategy for Selective Abrogation of Thrombospondin 1‐Induced Vascular Dysfunctions via Decoy recombinant CD47

Platelet-targeted thromboprophylaxis with a human serum albumin fusion drug: Preventing thrombosis and reducing cardiac ischemia/reperfusion injurywithout bleeding complications